Gene therapy of mesothelioma

Expert Opinion on Biological Therapy

Volumn 5, Issue 8, 2005, Pages 1039-1049

  Nelson, Delia J ^a   Robinson, Bruce W S ^b   Allan, Jane ^b   Van Der Most, Robert ^b  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cytokines; Intratumoural delivery; Suicide gene therapy; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; CYTOSINE DEAMINASE; DNA VACCINE; FLUCYTOSINE; GANCICLOVIR; HERPESVIRUS VECTOR; INTERLEUKIN 12; INTERLEUKIN 2; LENTIVIRUS VECTOR; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PARVOVIRUS VECTOR; PROTEIN P16INK4A; PROTEIN P53; RECOMBINANT DNA; RETROVIRUS VECTOR; THYMIDINE KINASE;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; DENDRITIC CELL; DNA PROTEIN COMPLEX; FOWLPOX VIRUS; GENE GUN; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOMODULATION; MALIGNANT MESOTHELIOMA; METASTASIS; NONHUMAN; REVIEW; TREATMENT OUTCOME; TUMOR CELL; TUMOR LOCALIZATION; TUMOR REGRESSION; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALS; DENDRITIC CELLS; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; MESOTHELIOMA; MOLECULAR BIOLOGY; VIRUSES;

EID: 23844558590     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.8.1039     Document Type: Review

References (101)

1. WAGNER JC, SLEGGS CA, MARCHAND P: Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med. (1960) 17:260-271.
2. MUSK AW, DE KLERK NH: Epidemiology of malignant mesothelioma in Australia. Lung Cancer (2004) 45(Suppl. 1):S21-S23.
3. MUSK AW, ROUSE IL, RIVERA B, DE KLERK NH, MCNULTY JC: Respiratory disease in non-smoking Western Australian goldminers. Br. J. Ind. Med. (1992) 49:750-754.
4. UPHAM JW, GARLEPP MJ, MUSK AW, ROBINSON BW: Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches. Thorax (1995) 50:887-893.
5. STEELE JP, KLABATSA A: Chemotherapy options and new advances in malignant pleural mesothelioma. Ann. Oncol. (2005) 16:345-351.
6. VOGELZANG NJ: Multimodality therapy in mesothelioma: role of chemotherapy. Thorac. Surg. Clin. (2004) 14:531-542.
7. ANDREOPOULOU E, ROSS PJ, O'BRIEN ME et al.: The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann. Oncol. (2004) 15:1406-1412.
8. MUSK AW, DE KLERK NH, ECCLES JL et al.: Wittenoom, Western Australia: a modern industrial disaster. Am. J. Ind. Med. (1992) 21:735-747.
9. MOOLTEN FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. (1986) 46:5276-5281.
10. MOOLTEN FL, WELLS JM: Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. (1990) 82:297-300.
11. TIBERGHIEN P, REYNOLDS CW, KELLER J et al.: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood (1994) 84:1333-1341.
12. ELION GB: The chemotherapeutic exploitation of virus-specified enzymes. Adv. Enzyme Regul. (1980) 18:53-66.
13. FREEMAN SM, WHARTENBY KA, FREEMAN JL, ABBOUD CN, MARROGI AJ: in situ use of suicide genes for cancer therapy. Semin. Oncol. (1996) 23:31-45.
14. FREEMAN SM, ABBOUD CN, WHARTENBY KA et al.: The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. (1993) 53:5274-5283.
15. HIRSCHOWITZ EA, OHWADA A, PASCAL WR, RUSSI TJ, CRYSTAL RG: In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum. Gene Ther. (1995) 6:1055-1063.
16. ELSHAMI AA, KUCHARCZUK JC, ZHANG HB et al.: Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum. Gene Ther. (1996) 7:141-148.
17. POPE IM, POSTON GJ, KINSELLA AR: The role of the bystander effect in suicide gene therapy. Eur. J. Cancer (1997) 33:1005-1016.
18. SEACHRIST L: Successful gene therapy has researchers looking for the bystander effect. J. Natl. Cancer Inst. (1994) 86:82-83.
19. HAMEL W, MAGNELLI L, CHIARUGI VP, ISRAEL MA: Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. (1996) 56:2697-2702.
20. KUCHARCZUK JC, RAPER S, ELSHAMI AA et al.: Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates. Hum. Gene Ther. (1996) 7:2225-2233.
21. LANUTI M, GAO GP, FORCE SD et al.: Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum. Gene Ther. (1999) 10:463-475.
22. ESANDI MC, VAN SOMEREN GD, VINCENT AJ et al.: Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther. (1997) 4:280-287.
23. SMYTHE WR, KAISER LR, HWANG HC et al.: Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann. Thorac. Surg. (1994) 57:1395-1401.
24. SMYTHE WR, HWANG HC, AMIN KM et al.: Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res. (1994) 54:2055-2059.
25. SMYTHE WR, HWANG HC, ELSHAMI AA et al.: Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. (1995) 222:78-86.
26. HWANG HC, SMYTHE WR, ELSHAMI AA et al.: Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am. J. Respir. Cell Mol. Biol. (1995) 13:7-16.
27. TREAT J, KAISER LR, STERMAN DH et al.: Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a Phase I trial (BB-IND 6274). Hum. Gene Ther. (1996) 7:2047-2057.
28. STERMAN DH, TREAT J, LITZKY LA et al.: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a Phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. (1998) 9:1083-1092.
29. MOLNAR-KIMBER KL, STERMAN DH, CHANG M et al.: Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy Phase I clinical trial for localized mesothelioma. Hum. Gene Ther. (1998) 9:2121-2133.
30. TAKAHASHI T, CARBONE D, NAU MM et al.: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. (1992) 52:2340-2343.
31. METCALF RA, WELSH JA, BENNETT WP et al.: p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. (1992) 52:2610-2615.
32. GIULIANO M, CATALANO A, STRIZZI L, VIANALE G, CAPOGROSSI M, PROCOPIO A: Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J. Mol. Med. (2000) 5:591-596.
33. TESTA JR, GIORDANO A: SV40 and cell cycle perturbations in malignant mesothelioma. Semin. Cancer Biol. (2001) 11:31-38.
34. WONG L, ZHOU J, ANDERSON D, KRATZKE RA: Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer (2002) 38:131-136.
35. FRIZELLE SP, RUBINS JB, ZHOU JX, CURIEL DT, KRATZKE RA: Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther. (2000) 7:1421-1425.
36. YANG CT, YOU L, UEMATSU K, YEH CC, MCCORMICK F, JABLONS DM: p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res. (2001) 61:5959-5963.
37. HIRAO T, BUENO R, CHEN CJ, GORDON GJ, HEILIG E, KELSEY KT: Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis (2002) 23:1127-1130.
38. LECHNER JF, TESFAIGZI J, GERWIN BI: Oncogenes and tumor-suppressor genes in mesothelioma-a synopsis. Environ. Health Perspect. (1997) 105(Suppl. 5):1061-1067.
39. PAPP T, SCHIPPER H, PEMSEL H et al.: Mutational analysis of N-ras, p53, p16INK4a, p14ARF, CDK4 genes in primary human malignant mesotheliomas. Int. J. Oncol. (2001) 18:425-433.
40. YANG CT, YOU L, LIN YC, LIN CL, MCCORMICK F, JABLONS DM: A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res. (2003) 23:33-38.
41. FRIZELLE SP, GRIM J, ZHOU J et al.: Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene (1998) 16:3087-3095.
42. PATAER A, SMYTHE WR, YU R et al.: Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines. J. Thorac. Cardiovasc. Surg. (2001) 121:61-67.
43. MOHIUDDIN I, CAO X, FANG B, NISHIZAKI M, SMYTHE WR: Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Ther. (2001) 8:547-554.
44. RUSSELL SJ: Replicating vectors for cancer therapy: a question of strategy. Semin. Cancer Biol. (1994) 5:437-443.
45. LANUTI M, KOURI CE, FORCE S et al.: Use of protamine to augment adenovirus-mediated cancer gene therapy. Gene Ther. (1999) 6:1600-1610.
46. ELSHAMI AA, KUCHARCZUK JC, STERMAN DH et al.: The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. (1995) 222:298-307; 307-310.
47. SMYTHE WR, HWANG HC, ELSHAMI AA, AMIN KM, ALBELDA SM, KAISER LR: Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy. J. Thorac. Cardiovasc. Surg. (1995) 109:626-630; discussion 630-631.
48. HUSTINX R, SHIUE CY, ALAVI A et al.: Imaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography and. Eur. J. Nucl. Med. (2001) 28:5-12.
49. KUCHARCZUK JC, RANDAZZO B, CHANG MY et al.: Use of a 'replication- restricted' herpes virus to treat experimental human malignant mesothelioma. Cancer Res. (1997) 57:466-471.
50. MUKHERJEE S, HAENEL T, HIMBECK R et al.: Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther. (2000) 7:663-670.
51. CAMINSCHI I, VENETSANAKOS E, LEONG CC, GARLEPP MJ, ROBINSON BW, SCOTT B: Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12. Am. J. Respir. Cell Mol. Biol. (1999) 21:347-356.
52. ROBINSON BW, MUKHERJEE SA, DAVIDSON A et al.: Cytokine gene therapy or infusion as treatment for solid human cancer. J. Immunother. (1998) 21:211-217.
53. NOWAK AK, LAKE RA, KINDLER HL, ROBINSON BW: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin. Oncol. (2002) 29:82-96.
54. BIELEFELDT-OHMANN H, FITZPATRICK DR, MARZO AL, JARNICKI AG, MUSK AW, ROBINSON BW: Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model. J. Interferon Cytokine Res. (1995) 15:213-223.
55. DAVIDSON JA, MUSK AW, WOOD BR et al.: Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J. Immunother. (1998) 21:389-398.
56. DORVAL T, MATHIOT C, CHOSIDOW O et al.: IL-2 Phase II trial in metastatic melanoma: analysis of clinical and immunological parameters. Biotechnol. Ther. (1992) 3:63-79.
57. FITZPATRICK DR, MANNING LS, MUSK AW, ROBINSON BW, BIELEFELDT-OHMANN H: Potential for cytokine therapy of malignant mesothelioma. Cancer Treat. Rev. (1995) 21:273-288.
58. GATTACCECA F, PILATTE Y, BILLARD C et al.: Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma. Clin. Cancer Res. (2002) 8:3298-3304.
59. KRASTEV Z, KOLTCHAKOV V, VLADOV N et al.: A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol. Immunother. (2001) 50:226-227.
60. KRUKLITIS RJ, SINGHAL S, DELONG P et al.: Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J. Thorac. Cardiovasc. Surg. (2004) 127:123-130.
61. ODAKA M, WIEWRODT R, DELONG P et al.: Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy. Mol. Ther. (2002) 6:210-218.
62. UPHAM JW, MUSK AW, VAN HAZEL G, BYRNE M, ROBINSON BW: Interferon alpha and doxorubicin in malignant mesothelioma: a Phase II study. Aust. NZ. J. Med. (1993) 23:683-687.
63. FEARON ER, PARDOLL DM, ITAYA T et al.: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 60:397-403.
64. GOLUMBEK PT, LAZENBY AJ, LEVITSKY HI et al.: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 254:713-716.
65. ASHER AL, MULE JJ, KASID A et al.: Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. (1991) 146:3227-3234.
66. KUGLER A, STUHLER G, WALDEN P et al.: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. (2000) 6:332-336.
67. LEONG CC, MARLEY JV, LOH S, MILECH N, ROBINSON BW, GARLEPP MJ: Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma. Int. J. Cancer (1997) 71:476-482.
68. MUKHERJEE S, NELSON D, LOH S et al.: The immune anti-tumor effects of GM-CSF, B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther. (2001) 8:580-588.
69. SCHWARZENBERGER P, HARRISON L, WEINACKER A et al.: The treatment of malignant mesothelioma with a gene modified cancer cell line: a Phase I study. Hum. Gene Ther. (1998) 9:2641-2649.
70. SCHWARZENBERGER P, LEI D, FREEMAN SM et al.: Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. Am. J. Respir. Cell Mol. Biol. (1998) 19:333-337.
71. HARRISON LH JR, SCHWARZENBERGER PO, BYRNE PS, MARROGI AJ, KOLLS JK, MCCARTHY KE: Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann. Thorac. Surg. (2000) 70:407-411.
72. BERNSEN MR, TANG JW, EVERSE LA, KOTEN JW, OTTER WD: Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Cancer Treat. Rev. (1999) 25:73-82.
73. PANTUCK AJ, BELLDEGRUN AS: Phase I clinical trial of interleukin 2 (IL-2) gene therapy for prostate cancer. Curr. Urol. Rep. (2001) 2:33.
74. TARTOUR E, MEHTALI M, SASTRE-GARAU X et al.: Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br. J. Cancer (2000) 83:1454-1461.
75. CASTAGNETO B, ZAI S, MUTTI L et al.: Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a Phase II study on 31 consecutive patients. Lung Cancer (2001) 31:303-310.
76. ODAKA M, STERMAN DH, WIEWRODT R et al.: Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res. (2001) 61:6201-6212.
77. LANUTI M, RUDGINSKY S, FORCE SD et al.: Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res. (2000) 60:2955-2963.
78. RUDGINSKY S, SIDERS W, INGRAM L, MARSHALL J, SCHEULE R, KAPLAN J: Antitumor activity of cationic lipid complexed with immunostimulatory DNA. Mol. Ther. (2001) 4:347-355.
79. CAUX C, LIU YJ, BANCHEREAU J: Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol. Today (1995) 16:2-4.
80. STEINMAN RM: The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. (1991) 9:271-296.
81. ARTHUR JF, BUTTERFIELD LH, ROTH MD et al.: A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. (1997) 4:17-25.
82. TUTING T, WILSON CC, MARTIN DM et al.: Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J. Immunol. (1998) 160:1139-1147.
83. NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. (1998) 4:328-332.
84. MUKHERJEE S, UPHAM J, RAMSHAW I, ROBINSON BW, NELSON DJ: Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12. Cancer Gene Ther. (2003) 10:591-602.
85. SCHLESINGER S: Alphavirus vectors: development and potential therapeutic applications. Expert Opin. Biol. Ther. (2001) 1:177-191.
86. YING H, ZAKS T, WANG R et al.: Cancer therapy using a self-replicating RNA vaccine. Nat. Med. (1999) 5:823-827.
87. COLMENERO P, CHEN M, CASTANOS-VELEZ E, LILJESTROM P, JONDAL M: Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int. J. Cancer (2002) 98:554-560.
88. REN W, STRUBE R, ZHANG X, CHEN SY, HUANG XF: Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res. (2004) 64:6645-6651.
89. RACANELLI V, BEHRENS SE, ALIBERTI J, REHERMANN B: Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity. Immunity (2004) 20:47-58.
90. KHROMYKH AA, KENNEY MT, WESTAWAY EG: Trans-complementation of flavivirus RNA polymerase gene NS5 by using Kunjin virus replicon-expressing BHK cells. J. Virol. (1998) 72:7270-7279.
91. BERGLUND P, SMERDOU C, FLEETON MN, TUBULEKAS I, LILJESTROM P: Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. (1998) 16:562-565.
92. LEITNER WW, HWANG LN, DEVEER MJ et al.: Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. (2003) 9:33-39.
93. HSU KF, HUNG CF, CHENG WF et al.: Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. (2001) 8:376-383.
94. LEITNER WW, YING H, DRIVER DA, DUBENSKY TW, RESTIFO NP: Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. (2000) 60:51-55.
95. RESTIFO NP: Vaccines to die for. Nat. Biotechnol. (2001) 19:527-528.
96. SINGH M, BRIONES M, OTT G, O'HAGAN D: Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA (2000) 97:811-816.
97. GREGORIADIS G, BACON A, CAPARROS-WANDERLEY W, MCCORMACK B: A role for liposomes in genetic vaccination. Vaccine (2002) 20(Suppl. 5):B1-B9.
98. DIEBOLD SS, LEHRMANN H, KURSA M, WAGNER E, COTTEN M, ZENKE M: Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. Hum. Gene Ther. (1999) 10:775-786.
99. PASETTI MF, BARRY EM, LOSONSKY G et al.: Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J. Virol. (2003) 77:5209-5217.
100. MENDES R, O'BRIEN ME, MITRA A et al.: Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. Br. J. Cancer (2002) 86:336-341.
101. PANDHA HS, MORTIMER P, SOUBERBEILLE B, MCCOUBRIE P, O'BRIEN ME: Cutaneous toxicity after intradermal vaccination with Mycobacterium vaccae against lung cancer and malignant mesothelioma. Br. J. Dermatol. (2001) 144:648-649.